1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Serbia Pharmaceuticals and Healthcare Report Q2 2016

Serbia Pharmaceuticals and Healthcare Report Q2 2016

  • April 2016
  • -
  • Business Monitor International
  • -
  • 76 pages

Includes 3 FREE quarterly updates

BMI View: The Serbian pharmaceutical and healthcare market remains one of the least attractive withinthe CEE region for foreign drugmakers. Government cost containment, implemented through severe drugprice cuts by the RFZO, will dampen growth. Furthermore, an increasing reliance on private healthspending will impact pharmaceutical sales as the worsening macroeconomic outlook will reduce consumerspending power.Headline Expenditure ProjectionsPharmaceuticals: RSD91.42bn (USD840mn) in 2015 to RSD87.40bn (USD762mn) in 2016; -4.4% inlocal currency terms and -9.3% in US dollar terms. Forecast unchanged from Q116.Healthcare: RSD372.29bn (USD3.42bn) in 2015 to RSD362.75bn (USD3.15bn) in 2016; -2.6% in localcurrency terms and -7.6% in US dollar terms. Forecast unchanged from Q116.

Table Of Contents

Serbia Pharmaceuticals and Healthcare Report Q2 2016
BMI Industry View 7
Table: Headline Pharmaceuticals and Healthcare Forecasts (Serbia 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Serbia 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Serbia 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 19
Patented Drug Market Forecast 20
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 21
Generic Drug Market Forecast 22
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 23
OTC Medicine Market Forecast 24
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Serbia 2012-2020) 25
Pharmaceutical Trade Forecast 26
Table: Pharmaceutical Trade Data And Forecasts (Serbia 2014-2020) 27
Table: Pharmaceutical Trade Data And Forecasts local currency (Serbia 2014-2020) 28
Industry Risk/Reward Index 29
Central And Eastern Europe Risk/Reward Index 29
Serbia Risk/Reward Index 35
Rewards 35
Risks 36
Regulatory Review 38
Intellectual Property Environment 39
Pricing Regime 43
Reimbursement Regime 45
Market Overview 47
Healthcare Sector 48
Table: Healthcare Resources (Serbia 2010-2015) 51
Table: Healthcare Personnel (Serbia 2010-2015) 51
Table: Healthcare Activity (Serbia 2010-2015) 52
Research and Development 52
Clinical Trials 53
Epidemiology 54
Competitive Landscape 58
Research-Based Industry 58
Table: Table: Multinational Market Activity 58
Generic Drugmakers 59
Pharmaceutical Distribution 59
Company Profile 60
Hemofarm (Stada) 60
Galenika 63
Demographic Forecast 66
Table: Population Headline Indicators (Serbia 2005-2025) 67
Table: Population By Age Group (Serbia 2005-2025) 67
Table: Population By Age Group % (Serbia 2005-2025) 68
Glossary 70
Methodology 72
Pharmaceutical Expenditure Forecast Model 72
Healthcare Expenditure Forecast Model 72
Notes On Methodology 73
Risk/Reward Index Methodology 74
Index Overview 75
Table: Pharmaceutical Risk/Reward Index Indicators 75
Indicator Weightings 76

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.